JP2015526446A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526446A5
JP2015526446A5 JP2015527590A JP2015527590A JP2015526446A5 JP 2015526446 A5 JP2015526446 A5 JP 2015526446A5 JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015526446 A5 JP2015526446 A5 JP 2015526446A5
Authority
JP
Japan
Prior art keywords
seq
antibody
peptide
bind
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527590A
Other languages
English (en)
Japanese (ja)
Other versions
JP6664219B2 (ja
JP2015526446A (ja
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/en
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/en
Application filed filed Critical
Priority claimed from PCT/US2013/055015 external-priority patent/WO2014028668A2/en
Publication of JP2015526446A publication Critical patent/JP2015526446A/ja
Publication of JP2015526446A5 publication Critical patent/JP2015526446A5/ja
Application granted granted Critical
Publication of JP6664219B2 publication Critical patent/JP6664219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527590A 2012-08-14 2013-08-14 幹細胞増強治療法 Active JP6664219B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
USPCT/US2012/060684 2012-10-17
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction
USPCT/US2013/025981 2013-02-13
PCT/US2013/025981 WO2013123084A1 (en) 2012-02-13 2013-02-13 Method for detecting circulating fetal cells
US201361837560P 2013-06-20 2013-06-20
US61/837,560 2013-06-20
PCT/US2013/055015 WO2014028668A2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017238427A Division JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法

Publications (3)

Publication Number Publication Date
JP2015526446A JP2015526446A (ja) 2015-09-10
JP2015526446A5 true JP2015526446A5 (enExample) 2016-10-06
JP6664219B2 JP6664219B2 (ja) 2020-03-13

Family

ID=50101604

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015527590A Active JP6664219B2 (ja) 2012-08-14 2013-08-14 幹細胞増強治療法
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017238427A Active JP6757712B2 (ja) 2012-08-14 2017-12-13 幹細胞増強治療法
JP2020037396A Pending JP2020109101A (ja) 2012-08-14 2020-03-05 幹細胞増強治療法
JP2021181985A Pending JP2022025136A (ja) 2012-08-14 2021-11-08 幹細胞増強治療法

Country Status (8)

Country Link
US (2) US9932407B2 (enExample)
EP (1) EP2885000A4 (enExample)
JP (4) JP6664219B2 (enExample)
CN (3) CN108175856B (enExample)
AU (2) AU2013302620B2 (enExample)
CA (1) CA2882222A1 (enExample)
IL (1) IL237228B (enExample)
WO (1) WO2014028668A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
SG10201808867PA (en) 2014-04-07 2018-11-29 Minerva Biotechnologies Corp Anti-nme antibody
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017177199A2 (en) * 2016-04-08 2017-10-12 Iti Health, Inc. Plectin-1 binding antibodies and uses thereof
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CN112105380A (zh) 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変muc1*抗体およびその使用
KR20220016802A (ko) 2019-02-04 2022-02-10 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
US12049514B2 (en) 2020-06-08 2024-07-30 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
CA2442531A1 (en) * 2001-03-29 2002-10-10 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and antibodies to muc 1 proteins
ATE469648T1 (de) * 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
CA2482596A1 (en) * 2002-04-22 2003-10-30 Dyax Corp. Antibodies specific for mucin polypeptide
EP1536814A4 (en) * 2002-07-03 2006-02-15 Immunogen Inc ANTIQUE RPER AGAINST NON-SHED-MUC1 AND MUC16, AND ITS USES
CA2610292C (en) * 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
CN101652469B (zh) * 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
US10421819B2 (en) * 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
JP5773352B2 (ja) * 2008-10-28 2015-09-02 塩野義製薬株式会社 抗muc1抗体
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
EP4043552A1 (en) * 2009-06-11 2022-08-17 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
KR101853418B1 (ko) * 2010-06-16 2018-05-02 미네르바 바이오테크놀로지 코포레이션 암 세포의 역분화

Similar Documents

Publication Publication Date Title
JP2015526446A5 (enExample)
Gonzalez-Sanchez et al. The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
Kawaguchi et al. SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
CA2807942C (en) Erythrocyte-binding therapeutics
Takahashi et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen
JP2016519933A5 (enExample)
JP2019516663A5 (enExample)
JP2019519215A5 (enExample)
EA202190587A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
JP2010529026A5 (enExample)
JP2019513005A5 (enExample)
JP2017507936A5 (enExample)
JP2020506690A5 (enExample)
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
JP2019536426A5 (enExample)
AU2012342117A8 (en) Recombinant proteins and their therapeutic uses
JP2015506961A5 (enExample)
JP2019520038A5 (enExample)
RU2019113989A (ru) Лекарственное средство
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Lin et al. Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
JP2019531254A5 (enExample)
JP2019520059A5 (enExample)